JP2022525549A5 - - Google Patents

Info

Publication number
JP2022525549A5
JP2022525549A5 JP2021556556A JP2021556556A JP2022525549A5 JP 2022525549 A5 JP2022525549 A5 JP 2022525549A5 JP 2021556556 A JP2021556556 A JP 2021556556A JP 2021556556 A JP2021556556 A JP 2021556556A JP 2022525549 A5 JP2022525549 A5 JP 2022525549A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
mtor inhibitor
individual
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525549A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023366 external-priority patent/WO2020191053A1/en
Publication of JP2022525549A publication Critical patent/JP2022525549A/ja
Publication of JP2022525549A5 publication Critical patent/JP2022525549A5/ja
Priority to JP2025060500A priority Critical patent/JP2025118604A/ja
Pending legal-status Critical Current

Links

JP2021556556A 2019-03-19 2020-03-18 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与 Pending JP2022525549A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025060500A JP2025118604A (ja) 2019-03-19 2025-04-01 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962820842P 2019-03-19 2019-03-19
US201962820838P 2019-03-19 2019-03-19
US62/820,838 2019-03-19
US62/820,842 2019-03-19
PCT/US2020/023366 WO2020191053A1 (en) 2019-03-19 2020-03-18 Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025060500A Division JP2025118604A (ja) 2019-03-19 2025-04-01 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与

Publications (2)

Publication Number Publication Date
JP2022525549A JP2022525549A (ja) 2022-05-17
JP2022525549A5 true JP2022525549A5 (enExample) 2023-03-28

Family

ID=72519161

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556556A Pending JP2022525549A (ja) 2019-03-19 2020-03-18 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与
JP2025060500A Pending JP2025118604A (ja) 2019-03-19 2025-04-01 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025060500A Pending JP2025118604A (ja) 2019-03-19 2025-04-01 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与

Country Status (9)

Country Link
US (1) US20220054404A1 (enExample)
EP (1) EP3941551A4 (enExample)
JP (2) JP2022525549A (enExample)
KR (1) KR102936433B1 (enExample)
CN (2) CN120267635A (enExample)
AU (1) AU2020241730B2 (enExample)
CA (1) CA3133988A1 (enExample)
MX (1) MX2021011230A (enExample)
WO (1) WO2020191053A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100642T1 (it) 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
MX2021011230A (es) 2019-03-19 2022-03-11 Abraxis Bioscience Llc Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
IL292439B2 (en) 2019-10-28 2026-05-01 Abraxis Bioscience Llc Pharmaceutical preparations of albumin and rapamycin
CN114945358A (zh) * 2019-11-11 2022-08-26 阿布拉科斯生物科学有限公司 用于纳米颗粒组合物的生物标记
CN120187414A (zh) * 2022-11-25 2025-06-20 克利凯生物公司 用于靶向炎症性巨噬细胞的纳米平台以及包含其的用于预防或治疗炎症性疾病的组合物
KR20250081554A (ko) * 2023-11-29 2025-06-05 주식회사 에스엔바이오사이언스 시롤리무스 및 알부민을 포함하는 나노입자, 이를 포함하는 피하투여용 약제학적 조성물 및 이의 제조방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684730A (zh) * 2002-09-04 2005-10-19 梅里迪安医学技术公司 药品输送装置
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
EP3417859A1 (en) * 2007-03-07 2018-12-26 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
US10143700B2 (en) * 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
JP6309610B2 (ja) * 2013-03-14 2018-04-11 アブラクシス バイオサイエンス， エルエルシー 膀胱がんを処置する方法
JP6462859B2 (ja) * 2014-08-18 2019-01-30 ウィンドギャップ メディカル， インコーポレイテッド 携帯型薬剤混合及び送達装置並びに関連の方法
CA2963085C (en) * 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US20180177771A1 (en) * 2015-06-29 2018-06-28 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
SMT202100642T1 (it) * 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
JP2018521058A (ja) * 2015-06-29 2018-08-02 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法
CA2990705A1 (en) * 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
JP2019513737A (ja) * 2016-04-08 2019-05-30 ギリアード サイエンシーズ， インコーポレイテッド がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
KR102475256B1 (ko) * 2016-09-28 2022-12-08 아브락시스 바이오사이언스, 엘엘씨 미토콘드리아 및 대사 장애를 치료하는 방법
WO2018153984A1 (en) * 2017-02-23 2018-08-30 Universität Bern Mtor inhibitor-corticoid combination therapy for multiple sclerosis
WO2018153969A1 (en) * 2017-02-24 2018-08-30 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with radium-223 salt
KR20210024471A (ko) * 2018-05-22 2021-03-05 아브락시스 바이오사이언스, 엘엘씨 폐고혈압을 치료하기 위한 방법 및 조성물
MX2021011230A (es) 2019-03-19 2022-03-11 Abraxis Bioscience Llc Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.

Similar Documents

Publication Publication Date Title
Patel et al. Ordered mesoporous silica nanocarriers: An innovative paradigm and a promising therapeutic efficient carrier for delivery of drugs
RU2016143365A (ru) Рапамицин-содержащая композиция, вводимая путем ингаляции для лечения возрастных заболеваний
JP2005506367A5 (enExample)
SK137996A3 (en) Cancer treatment and metastasis prevention
JP2006514092A5 (enExample)
JP2024517085A5 (enExample)
CN107137417B (zh) 一种用于治疗恶病质的药物组合物及其应用
CN100490820C (zh) 单独包含去纤苷酸或与其它抗肿瘤剂联合的抗肿瘤制剂
JP2019503335A (ja) ジメチルアミノミケリオリドの使用
RU2063770C1 (ru) Способ лечения гнойно-воспалительных заболеваний легких
Karatieieva et al. Treatment of pyoinflammatory complications with individually selected ozone dose in patients with diabetes
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
CN104758304A (zh) 三七皂苷r1的医药用途
RU2122844C1 (ru) Способ лечения герпетического кератита с изъязвлением
AU784656B2 (en) Novel therapeutic use of enoxaparin
JP2023504205A5 (enExample)
JPH027293B2 (enExample)
RU2586043C1 (ru) Способ профилактики и лечения осложнений при лучевой терапии рака кожи
JP2004503472A (ja) ボーラスまたは間欠的な静脈内注入による、抗内毒素薬の投与
RU2066186C1 (ru) Средство для купирования приступов удушья при бронхиальной астме
WO2023011635A1 (en) New treatment of immunodeficiency disorder
CN102091062A (zh) 一种采取吸入给药紫杉醇治疗肺癌的方法
JP2609882B2 (ja) 脱髄性疾患治療薬
RU2103008C1 (ru) Способ стимуляции apud-системы
US20010041686A1 (en) Novel therapeutic application of enoxaparin